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Quick and accurate medical diagnosis is crucial for the successful treatment of a 
disease. Using machine learning algorithms, we have built two models to predict 
a hematologic disease, based on laboratory blood test results. In one predictive 
model, we used all available blood test parameters and in the other a reduced 
set, which is usually measured upon patient admittance. Both models produced 
good results, with a prediction accuracy of 0.88 and 0.86, when considering the 
list of five most probable diseases, and 0.59 and 0.57, when considering only the 
most probable disease. Models did not differ significantly from each other, which 
indicates that a reduced set of parameters contains a relevant “fingerprint” of 
a disease, expanding the utility of the model for general practitioner’s use and 
indicating that there is more information in the blood test results than physicians 
recognize. In the clinical test we showed that the accuracy of our predictive 
models was on a par with the ability of hematology specialists. Our study is the 
first to show that a machine learning predictive model based on blood tests 
alone, can be successfully applied to predict hematologic diseases and could 
open up unprecedented possibilities in medical diagnosis.
Machine learning has undergone significant development over the past decade and is 
already used successfully in many intelligent applications covering a wide array of data 
related problems1. One of the most intriguing questions is whether it can be successfully 
applied to the field of medical diagnostics and what kind of data is needed? There are 
several examples of the successful application of machine learning methods in specialized 
medical fields2-6, and most recently, a model capable of classifying skin cancer based on 
images of the skin, with a level of competence comparable to that of a dermatologist 
has been presented7. There are however, no successful applications of machine learning 
that would tackle the broader and more complex fields of medical diagnosis, such as 
hematology. 
Medical diagnosis is the process of determining which disease explains a person’s 
symptoms and signs. In a physician’s ability to arrive at a differential diagnosis and to plan 
quickly, his or her medical knowledge, skills and experience will play a significant role8. 
2In a diagnostic procedure, available information is complemented by additional data 
gathering, which can be obtained from a patient’s medical history, a physical examination 
and from various diagnostic tests, including clinical laboratory tests. Laboratory tests are 
used to confirm, exclude, classify or monitor diseases and to guide treatment9. However, 
the true power of laboratory test results is frequently underestimated, since clinical 
laboratories tend to report test results as individual numerical or categorical values, 
with physicians concentrating mainly on those values that fall outside a given reference 
range10. 
The clinical diagnosis of hematological diseases is primarily based on laboratory tests of 
blood and even the most skilled hematology specialist can overlook patterns, deviations 
and relations between the increasing numbers of blood parameters being measured 
in a modern laboratory. Alternatively, machine learning algorithms can easily handle 
hundreds of attributes (parameters) and are capable of detecting and utilizing the 
interactions among them, which makes this field of medicine particularly interesting for 
machine learning applications. Our hypothesis was that the “fingerprint” of a certain 
hematological disease that we find in blood test results values is sufficient for a machine 
learning based predictive model to suggest a plausible diagnosis, provided that it has 
learned to recognize it from a sufficiently large dataset of medical cases, described by 
clinical laboratory blood tests that are associated with a correct diagnosis determined 
by a hematology specialist, who has utilized all of the diagnostic procedures necessary 
to confirm it. 
In this study, we describe and evaluate two Smart Blood Analytics (SBA) hematological 
predictive models based on two different sets of clinical laboratory blood test results 
(with a different number of blood parameters) and coded diseases, and their evaluation. 
We evaluated both models in using stratified ten-fold cross-validation of 8233 cases, 
as well as 20 additional randomly selected hematological cases and compared their 
performance against an evaluation made by hematology and internal medicine 
specialists. We also present an illustrative example of how our SBA predictive model can 
help speed up the diagnostic process.
Materials and Methods
Study setting and population
We collected data provided by the Clinical Department of Hematology for patients 
admitted to the University Medical Centre Ljubljana (UMCL) between 2005 and 2015. 
The hospital is a tertiary referral center located in Ljubljana, Slovenia and serves a local 
population of 400,000 inhabitants. For each admitted adult patient (18+ years of age) 
we collected anonymized laboratory blood test results and their diagnoses made on 
admission and on discharge. To minimize any bias from previous treatments we only 
considered a patient’s first admittance during the sampling period. In total, we collected 
data on 8233 cases for which 371341 laboratory blood tests were performed. We then 
manually curated the data and identified 181 different blood tests that were performed 
at least 10 times (see Supplementary Table S1 online). On average 24.9% (45 parameters) 
were measured in every case (Fig. 1).
3Figure 1. Parameter coverage for 43 different hematological categories of diseases. Frequency of every 
parameter measured is depicted with different colors and marked on the scale bar. The orange line 
delineates the reduced set of 61 basic parameters from the 181 blood test parameters measured.
From 181 unique blood tests we further selected a reduced subset that contained 61 
of the most frequently measured basic blood parameters (see Supplementary Table S1 
online). We then excluded all of the specific laboratory tests that are used to confirm 
a specific diagnosis. On average 66.4%  (41 parameters) were measured for every case 
(Fig. 1).
To compare diagnostic performance of physician and our predictive models, we selected 
an additional 20 random anonymous cases, which had received their first hematological 
diagnoses in 2016 or 2017 (see Supplementary Data S2 online). The data included 
laboratory blood tests from 20 adult patients comprising 10 women and 10 men.
For recording purposes, the UMCL uses a modified International Statistical Classification 
of Diseases and Related Health Problems (ICD). Our learning models used recorded 
diseases to three-characters deep in the ICD hierarchy. In total, 43 different hematological 
categories of diseases were identified among the 8233 cases analyzed (Table 1, 
Supplementary Table S3 online).
4Table 1. Top ten most prevalent categories of diseases in UMCL, Division for  
Hematology.
ICD 
code
Disease Category Frequency Prevalence
D47 Other neoplasms of uncertain or unknown behaviour 
of lymphoid, haematopoietic and related tissue 1522 18.5%
D50 Iron deficiency anaemia 1190 14.5%
D69 Purpura and other haemorrhagic conditions 743 9.0%
C90 Multiple myeloma and malignant plasma cell neo-
plasms 739 9.0%
C91 Lymphoid leukaemia 696 8.5%
C92 Myeloid leukaemia 578 7.0%
D75 Other diseases of blood and blood-forming organs 547 6.6%
D46 Myelodysplastic syndromes 457 5.6%
D64 Other anaemias 218 2.7%
D45 Polycythaemia vera 204 2.5%
Other  1339 16.1%
Predictive model building using a random forest algorithm 
The random forest algorithm11 is a special kind of ensemble approach. Ensembles are 
a divide-and-conquer approach used to improve predictive performance in machine 
learning. Ensemble methods12,13 combine weak learners to form a strong learner. 
A random forest consists of many very small decision or regression trees. Each tree, 
individually, is a weak learner, while all the trees (i.e., a forest) taken together form a 
strong learner.
Several authors have shown that random forest algorithms perform well in most problem 
domains14, including medical diagnostics15,16. When compared with hundreds of other 
machine learning approaches applied to many datasets17, random forests emerged as 
the best performer overall.
Random forests are very fast both for training and for prediction, since they can be 
efficiently parallelized. They perform very well without any parameter tuning, however, 
they may over-fit particularly noisy data. They are also able to deal with unbalanced and 
missing data, as well as with huge numbers of attributes and classes (for classification). 
While our data has low noise (all blood parameters are determined automatically), it is 
highly dimensional (181 attributes – blood parameters) with many missing values (on 
average, <25% of parameters were measured for each patient) and has a relatively high 
number of classes (43), making random forests the logical choice. In our early experiments 
exploring other popular machine learning methods i.e., decision trees, SVM, and Naive 
Bayesian classifier, resulted in significantly lower performance scores.
5Smart Blood Analytics algorithm
The machine learning pipeline (Smart Blood Analytics algorithm) consists of several 
processing stages:1. Data acquisition: acquiring raw data from the database2. Data filtering: selecting only those blood tests performed at the start of the treat-
ment, and the final diagnosis as the machine learning supervisor3. Data preprocessing: canonizing blood parameters (match with our reference param-
eter database, filtering erroneous values, handling missing values (imputation)4. Data modeling: building the predictive model 5. Evaluation: evaluating the predictive model with stratified 10-fold cross-validation)
After having successfully evaluated the data, the predictive model is deployed from 
the Smart Blood Analytics website (www.smartbloodanalytics.com). If not, the process 
resumes at one of the earlier stages (data preprocessing or modeling) (Fig. 2).
Figure 2. Schematic representation of the Smart Blood Analytics (SBA) algorithm process
Evaluation of predictive models
The models were automatically evaluated using stratified tenfold cross-validation, where 
the folds are selected so that the distribution of diseases is approximately equal in all 
of the folds. The process was repeated 10 times; each time one fold was set aside for 
testing, while the remaining 9 folds were used for training. Results were used to make a 
statistical comparison of the model’s performance on all 8233 cases using the Wilcoxon 
signed-rank test, aggregated into confusion matrices, and performance measures such 
as diagnostic accuracy, specificity and sensitivity, as well as ROC curves.
ROC curves 
A common approach for evaluating machine learning results for classification 
(diagnostic) problems is to observe classification accuracy (true positive rate) obtained 
by trained classifiers using relevant data sets. However, this approach is valid only under 
6the assumption of uniform error costs (all errors are equally costly). In practice, this is 
often not the case. For example, in medical diagnostics, a false positive may result in 
unnecessary health care costs, while a false negative may endanger the patient’s life due 
to delayed treatment. It is therefore often better to observe how the trained classifier 
behaves in a more general setting.
A popular method for visualizing classifier behavior is by utilizing ROC curves18. A ROC 
curve depicts the relation between the classifier’s true positive rate (sensitivity) and 
false positive rate (1−specificity). For two-class problems and scoring classifiers i.e., a 
classifier, which produces a score for each possible class, and predicts the class with the 
maximum score, ROC curves are produced in a straightforward manner by ordering the 
maximum scores and varying the decision threshold19. The one-vs-all approach yields N 
ROC curves that can be useful in observing classifier performance for each class. Multi-
class problems with N classes, can be transformed into N two-class problems, where 
each problem deals with discriminating one class-vs-all other N− 1 classes. The predictive 
model’s performance is deemed useful for a certain disease (class) if the entire ROC 
curve is above the diagonal (possibly as close to the upper left corner as possible). ROC 
curves near the diagonal are of little use, as the predictive model’s performance in such 
cases is only marginally better than chance.
We applied two approaches that are suitable for observing overall classifier performance 
in multi-class problems: macro-averaging and micro-averaging20. In macro-averaging, 
the ROC curves for all N diseases were averaged regardless of their frequencies. In micro-
averaging the ROC curve was calculated anew, based upon true positive and false positive 
rates for all diseases (or equivalently, by weighting ROC curves by relative frequencies of 
respective diseases and then averaging them). 
Clinical test setting
We also made two clinical tests, first with five hematology specialists and second with 
eight non-hematology specialists from internal medicine with at least eight years of 
experience. Each individual physician in both groups received the laboratory blood 
test results from 20 cases and was asked to determine a maximum of five potential 
hematological diseases and to sort them by decreasing order of likelihood. The same 20 
cases were then used to make predictions using both predictive models. 
Web-based application and graphical representation of predictive model results
As part of our work we also developed a web-based application that enables the easy 
input of blood parameters and produces an innovative representation of the results. 
It is available upon registration for medical professionals at www.smartbloodanalytics.
com. It also includes a novel visualization method of the machine learning model’s 
results (Fig. 3), by showing the 10 most probable diseases depicted as a polar chart 
with varying radii. Each chart segment represents a possible disease. Each segment’s 
angle corresponds to the predicted (posttest) disease probability. The radius of each 
segment is proportional to the logarithm of the ratio between the posttest and pretest 
(prevalence) probability, also called the information score. The radius therefore depicts 
the information (in bits) that is provided by the blood tests that favor (or disfavor) the 
corresponding disease.
7r(x) = log predicted(x)
prevalence(x)
= log predicted(x)− log prevalence(x) (radius)
φ(x) = 2π predicted(x) (anglein radians)
In these two equations (1,2), r is the radius (information score) and ø the angle (predicted 
probability) of a disease x.  Positive radii correspond to information scores in favor of a 
given diagnosis, while negative radii indicate that blood tests speak against a particular 
disease (information score is negative). As we cannot depict negative radii, the inner 
circle in the graph offsets the radius zero (indifferent information). Negative radii is 
therefore represented inside the innermost circle.
If we look at the graph as a whole, it is strongly related, though not identically, to the 
Kullback-Leibler21,22 divergence between posttest (predicted) and pretest (prevalence) 
probability distributions. 
Figure 3. Graphical representation of the predictive model results. Ten most probable diseases are depicted 
in a polar chart with varying radii. Every chart slice represents a disease, while the angle corresponds to 
the predicted (posttest) disease probability, whereas its radius is proportional to the logarithm of the ratio 
between posttest and pretest (prevalence) probability or the information score. 
This way of visualizing the results (Fig. 3) emphasizes the most probable diseases, as 
well as the diseases with the highest information scores. To reach a final diagnosis, a 
physician should consider both kinds of salient diseases. This is especially useful since 
predicted probabilities may not be optimally calibrated, as machine learning classifiers 
often tend to favor the more frequent classes (diseases) and neglect the less frequent 
ones.
(1)
(2)
8Data availability
Both predictive models are available at www.smartbloodanalytics.com upon registration. 
Twenty clinical test cases with all the data and predicted results can be found in 
Supplementary S2 Data online. The study was approved by the Slovenian National 
Medical Ethics Committee (No. 103/11/15).
Results
Random forest predictive models
Utilizing a random forest algorithm, we generated two different predictive models: Smart 
Blood Analytics Hematology 181 (SBA-HEM181) that was trained with 181 different 
blood parameters and Smart Blood Analytics Hematology 61 (SBA-HEM061), trained 
with 61 parameters. Both training sets contained 43 different categories of diseases. 
We validated both classifiers using stratified tenfold cross-validation. The SBA-HEM181 
prediction accuracy was 59%. 
Surprisingly SBA-HEM061 performed on a par with the SBA-HEM181 predictive model, 
attaining a prediction accuracy of 57%. If the first five predictions are taken into account, 
the SBA-HEM181 and SBA-HEM061 model accuracy were 88% and 86%, respectively 
(Fig. 4). These results are remarkable given the small data coverage and more importantly, 
the small subset of data used for predictive model building in regard to the data that is 
needed for diagnosis. 
9Figure 4. Confusion matrix for the five most probable diseases for both predictive models (A) SBA-
HEM181 and (B) for SBA-HEM61. Each column of the matrix represents the instances in the predicted 
diseases, while each row represents the instances in the actual diseases. The frequencies are marked 
on a logarithmic scale. 
Judging from both AUCs and the shape of the ROC curves (Fig. 5) SBA-HEM061 performed 
slightly better for the less prevalent diseases. Of Interest are the differences between 
the macro-averaged and micro-averaged ROC curves. The micro-averaged ROC curve 
lies above the macro-averaged one, which indicates that both predictive models, on 
average, underperform in the case of rare diseases (Fig. 5). 
Figure 5. Macro- and micro-averaged ROC curves with (a) a full set of 181 parameters and (b) a basic set 
of 61 parameters. The curves almost overlap while the AUC are almost identical.
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The ROC curves for SBA-HEM181 (Fig. 5A) and SBA-HEM061 models (Fig. 5B) are very 
similar and have practically the same area under the curves (AUC) showing that both 
models perform equally. We confirmed this hypothesis by applying the Wilcoxon signed 
rank test23. The null hypothesis H
0
 was that the median ranking of correct predictions for 
both models are significantly different. Not surprisingly, the p-values obtained on 8233 
results using a tenfold cross-validation show that we cannot reject the null hypothesis 
(p>0.35). We can therefore conclude that the ranking of correct predictions do not differ 
significantly between the two models, i.e., the reduced model performs as well as the 
complete one.
Model versus physician comparison
To compare the performance of our predictive models with that of a physicians, based only 
on laboratory blood tests as the input data, we performed a clinical test. Five hematology 
specialists and 8 specialists of internal medicine were given 20 hematological cases. Our 
classifier achieved an accuracy of 0.60 (0.55 SBA-HEM61) compared to an accuracy of 
0.62 achieved by the hematology specialists (Fig. 6A) and an accuracy of 0.26 achieved 
by the non-hematology internal medicine specialists (Fig. 6C). When taking into account 
the first five predicted diseases, accuracy increases to 0.90 for the prediction model 
SBA-HEM181 (0.85 SBA-HEM61) and is 0.77 for the hematology specialists (Fig. 6B). The 
Internal medicine specialists only predicted one possible disease. 
Figure 6. Comparison of the accuracy of internal medicine specialists with both predictive models 
(A) Accuracy of the five hematology specialists compared to both predictive models, when taking in to 
the account the five most probable predicted diseases. (B) Accuracy of the five hematology specialists 
compared to both predictive models, when taking in to the account only the most probable predicted 
disease. (C) Accuracy of the eight non-hematology internal medicine specialists compared to both 
predictive models, when taking in to account the most probable predicted disease
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To compare the physicians’ results with the results from our models, we applied the 
Wilcoxon signed rank tests23. The statistical test was performed on a paired sample of 
20 results, one set from the physicians, and one from either of the predictive models 
(SBA-HEM181 or SBA-HEM61). The null hypothesis was that the results (median ranks of 
correct predictions) of the hematology specialists and that of the models do not differ 
significantly. For SBA-HEM181 and SBA-HEM61 the Wilcoxon signed-rank test established 
that there is no significant difference (p>0.05) between either of the models and the 
hematology specialists. When compared with internal medicine specialists, the test 
result was significant (p<0.01) in favor of the predictive models, which perform better 
(Fig. 3).
Illustrative example
A 65-year old man that had been exhibiting diffuse abdominal pain, tiredness, weight 
loss, back pain and spontaneous bruising over the last 9 months was admitted to the 
UMCL for hormonal evaluation of an adrenal tumor revealed by computer tomography 
five months earlier. The standard hormonal evaluation excluded the adrenal tumor’s 
hormonal autonomy, but serum protein evaluation revealed increased serum free light 
chains indicating a plasma cell disorder. A bone marrow biopsy was performed and the 
patient was discarded without diagnosis and treatment, while waiting for the bone 
marrow histology results. After discharge, the laboratory results were analyzed on the 
Smart Blood Analytics website and SBA-HEM181 model proposed plasmocytoma (ICD 
category code D90) as the second most probable disease using only admission laboratory 
results and as the most probable hematological disease using all of the patients laboratory 
results during hospitalization (Fig. 3). His “normal” laboratory results from two years 
earlier were analyzed also and the SBA-HEM181 model proposed plasmocytoma as the 
fourth most likely disease at that time. The patient has since received the hematology 
specialist’s confirmation that he had plasmocytoma and amyloidosis (ICD category code 
E85) one month after admission. 
This example demonstrates how our model could help physicians in facilitating the 
diagnostic procedure and in the future reduce the number of tests, particularly in 
insidious diseases, such as plasmocytoma, that begins several years before symptoms 
appear. It could help patients in the process of requesting a second opinion. 
Discussion
In this study, we show that the machine learning approach, using a random forest algorithm 
with a large amount of multianalyte sets of hematologic disease laboratory blood test 
results, is able to interpret the results and predict diseases on a par with an experienced 
hematology specialist, while outperforming an internal medicine specialist by a margin 
of more than two. Our study consists of 43 possible disease categories (classes), with 
a majority class prevalence of 18.4% and a Shannon entropy of 3.95 bit, which is fairly 
close to the theoretical maximum of 5.42 for 43 classes. This problem is difficult for a 
machine learning task in the medical domain; according to the UCI repository24, where 
more than 50% of medical datasets consist of only two classes, dealing with a single 
disease (present/absent). In addition, more than 75% of missing attribute (parameter) 
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values do not help either. According to these numbers, a classification (diagnostic) 
accuracy of 0.57 (SBA-HEM61) and 0.59 (SBA-HEM181) for the most probable disease 
represents excellent results, comparable to that of a hematology specialist and is far 
beyond the expected accuracy scores for the simple majority (0.184) or the random 
predictive model (0.093).
Our predictive models’ usefulness in hematological diseases diagnosis was also 
confirmed in a clinical test in which both predictive models were able to diagnose the 
type of hematological diseases as well as an experienced hematology specialist and 
significantly better than a general internal medicine specialists. We were able to show 
that the accuracy of prediction of SBA-HEM061 and SBA-HEM181, using admission 
blood laboratory tests, were 0.55 and 0.60, respectively, while hematology specialist’s 
accuracy was 0.60; the three results are not significantly different (Wilcoxon signed-rank 
test, p>0.05,). However, taking into account the five most probable diagnoses proposed 
by SBA-HEM181 and the hematology specialists, the accuracy of SBA-HEM181 and 
that of the hematology specialists improved to 0.90 and 0.77, respectively (significant 
difference, p<0.05). 
Accordingly, SBA could help those physicians not specialized in hematology in facilitating 
the diagnostic procedure, especially by suggesting proper and early patient’s referral. 
In addition, this study showed that many laboratory tests are not needed to arrive 
at a correct diagnosis, but may be otherwise useful for additional confirmations. The 
predictive model SBA-HEM061, trained on only a third of the available laboratory 
variables (routine laboratory tests that were most frequently used by physicians), was 
equally successful in predicting the most probable diseases, determined by hematology 
specialists (57% accuracy). Moreover, the accuracy of SBA-HEM061 for predicting the 
discharge diagnoses determined by hematology specialists increased to 90%. This 
suggests there is substantial information redundancy as well as interdependency in 
laboratory tests, since the accuracy of SBA-HEM061 in predicting diagnoses based on 
laboratory results was equivalent to using all 181 laboratory tests and the 61 routinely 
used laboratory tests. From this we can conclude that a machine learning approach in 
laboratory diagnostics could aid physicians in making early diagnoses of a disease using 
fewer laboratory tests9.
The results of this study are encouraging, and oppose established practice and reflections 
of physicians. In clinical practices, a physician’s ability to quickly reach a diagnosis and 
decide on a management plan is extraordinary and resembles an “art”, since much of the 
process involves skills in clinical decision-making, the essence of which most physicians 
find hard to describe in an actionable manner. This view is further reinforced by a study 
showing that a history of a patient, physical examination and laboratory investigation 
led to a final diagnosis in 76%, 10% and 11% of the cases, respectively25. Accordingly, 
most of physicians are convinced that laboratory test results, viewed in isolation, are 
typically of a limited diagnostic value in a differential diagnosis, especially in situations 
where medical knowledge and experience play a significant role10. Such an opinion is 
understandable, considering the absence of published articles on advanced analytical 
and machine learning approaches in blood laboratory diagnostics. Therefore, it would be 
useful for physicians to use a machine learning approach in the interpretation of blood 
laboratory test results. Instead of ordering an increasing number of unnecessary and 
costly tests, physicians could improve his or her interpretation of the test data by using 
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clinical decision support systems, based on a machine learning approach. These machine 
learning models could help physicians in the interpretation of multianalyte sets of many 
individual blood laboratory test results. This is important, since it seems that physicians 
use even individual laboratory tests insufficiently. In 15% of cases, physicians admitted 
to not completely understanding what tests they were ordering and 25% admitted to 
being confused by the results that come back26. The sheer volume of tests available and 
the rapid rate of their increase make a physicians’ understanding and proper use of the 
results to improve the outcome even worse.
Machine learning in blood laboratory tests interpretation could be particularly useful 
for general practitioners and other physicians not familiar with detailed hematological 
diagnostics, since our models predict the most probable hematological diseases, using 
only a patients’ blood laboratory results. This can also aid physicians to correctly refer 
patients. The usefulness of such models would be greatly improved if they were to 
become an integral part of medical information systems i.e., as decision support for 
health care providers and spontaneously by including a list of probable diseases in the 
laboratory report. At the same time, it could stimulate the production of consolidated, 
large-scale, digitalized databases of patient information that, by itself, could change the 
course of medicine. 
In a time of increasing patient awareness and a desire to be actively involved in 
treatment, patients and their relatives could use a diagnostic tool like ours, in the process 
of requesting a second opinion. Thus, user-friendly Smart Blood Analytics website (www.
smartbloodanalytics.com) with numerical and graphical representation of proposed 
diseases was developed and tested prospectively on actual patients. The most interesting 
example was our illustrative case, in which our model was able to predict the correct 
disease from laboratory results obtained several years prior to the occurrence of the 
existing disease and its symptoms. 
The excellent results we obtained in our study in the application of machine learning 
in hematology has encouraged further work within the field of internal medicine as a 
whole. Models built for other fields of internal medicine show promising results.
Conclusion
Every disease originates from or causes changes on a cellular and molecular level, which 
are directly or indirectly almost always detectable in changes in blood parameter values. 
These changes can be huge and physicians observe them by monitoring the blood 
parameter values that are out of the normal ranges. However, small changes and/or 
interactions between multiple different blood parameters that are equally important 
for detecting pathological patterns (disease “fingerprints”), can be easily overlooked. 
This implies that the value of blood test results is often underestimated. Furthermore, a 
machine learning approach is able to recognize disease-related blood laboratory patterns 
beyond current medical knowledge. This results in higher diagnostic accuracy compared 
to traditional quantitative interpretation based on reference ranges for blood parameters. 
Taking a machine learning approach in blood laboratory-based diagnosis could lead to a 
fundamental change in differential diagnosis and result in the modification of currently 
accepted guidelines. Nevertheless, physicians will always be needed to interact with 
patients4 and should retain access to all raw laboratory data.
In conclusion, a machine learning approach using a random forest algorithm with a 
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sufficiently large data set indicates substantial information redundancy and unobserved 
potential of laboratory blood test results in diagnosing disease. SBA predictive models 
show great promise in medical laboratory diagnosis that could be of considerable value 
to physicians and patients alike, while having widespread beneficial impacts on the cost 
of healthcare. 
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